FDA Drafts Rules for Updating Drug Safety Labels
Published Date: 9/19/2025
Notice
Summary
The FDA just released a draft guide to help drug makers update safety labels when new risks pop up after a drug is approved. This affects companies that hold drug or biological product applications, making sure labels stay accurate and safe. The updated guide reflects recent law changes and current FDA rules, so watch for final rules soon—this could impact how quickly companies must act and possibly their costs.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
FDA may require post‑approval label changes
The draft guidance explains that under Section 505(o)(4) the FDA can require holders of certain drug and biological product applications to make labeling changes when new safety information appears after approval and FDA determines it should be added to the label. This requirement applies to application holders for those products.
Guidance updates include 2018 reduced‑effectiveness rule
The draft revises and, when finalized, will replace the July 2013 guidance. It adds information reflecting Congress' 2018 changes to the definition of adverse drug experience about reduced effectiveness and updates FDA processes and procedures for safety labeling changes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-18148, Self-Regulatory Organizations; Municipal Securities Rulemaking Board; Order Approving a Proposed Rule Change To Amend Rule G-14 RTRS Procedures Under MSRB Rule G-14 Regarding the Timing of Reporting Transactions in Municipal Securities to the MSRB and To Make a Related Amendment to Rule G-12
The Municipal Securities Rulemaking Board (MSRB) is keeping the current 15-minute rule for brokers and dealers to report municipal bond trades, instead of shortening it. They’re also removing some exceptions and updating related rules to keep things clear and consistent. This means no rushed reporting changes for now, helping everyone stay on the same page without extra costs or confusion.
Next: 2025-18154, Foreign Endangered Species; Receipt of Permit Applications
The U.S. Fish and Wildlife Service is asking the public to share their thoughts on requests to work with endangered animals from other countries. These activities usually need special permission to make sure the animals stay safe. If you care about protecting these rare species, now’s the time to speak up before permits are approved!